Brain (and spinal cord) tumours
Open
Phase 1
This trial is looking at amivantamab for glioblastoma.
It is for people whose brain tumours have come back or the last treatment didn’t work.
You pronounce amivantamab as amee-van-tah-mab.
The 5G-EMERALD trial is part of a large research programme looking at new treatments for brain tumours. The research programme is called 5G: A Next-Generation aGile Genomically Guided Glioma platform trial. It is called the 5G platform trial for short.
Cancer Research UK supports this trial.
Recruitment start: 24 October 2024
Recruitment end: 28 July 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Juanita Lopez
Institute of Cancer Research (ICR)
Cancer Research UK
Minderoo Foundation
The Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge
This is Cancer Research UK trial number CRUK/23/004.
Last reviewed: 02 Feb 2026
CRUK internal database number: 20140